NCT03956017 (ACE) is a EARLY_PHASE1 clinical trial of Ubiquinone in Myocardial Injury, sponsored by Minneapolis Veterans Affairs Medical Center.

Who is sponsoring NCT03956017?

NCT03956017 is sponsored by Minneapolis Veterans Affairs Medical Center.

What drugs are being tested in NCT03956017?

Interventions in NCT03956017: Ubiquinone, Placebo.

What condition does NCT03956017 study?

NCT03956017 studies Myocardial Injury.

Is NCT03956017 still recruiting?

NCT03956017 is currently status unknown. Last updated 31 August 2021.

Last reviewed 2021-08-31 · How we verify

NCT03956017: ACE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-oxidant Therapy and Postoperative Cardiac Events (ACE) Trial, Preoperative Intervention in Vascular Surgery

Status unknown EARLY_PHASE1 Last updated 31 August 2021

What this trial tests

EARLY_PHASE1 trial testing Ubiquinone in Myocardial Injury in 341 participants. Status unknown.

Timeline

5 August 2013

Primary endpoint
4 August 2022

4 August 2022

Quick facts

Lead sponsor	Minneapolis Veterans Affairs Medical Center
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	341
Start date	5 August 2013
Primary completion	4 August 2022
Estimated completion	4 August 2022
Sites	1 location across United States

Drugs / interventions tested

Ubiquinone — full drug profile →
Placebo

Conditions studied

Myocardial Injury — all drugs for Myocardial Injury →

Sponsor

Minneapolis Veterans Affairs Medical Center

Who can join

Eligibility, any sex, with Myocardial Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

N Terminal (NT)-Pro b-type natriuretic peptide (BNP) levels provide incremental value in perioperative risk assessment prior to major non-cardiac surgery. The investigators will test whether pharmacologically lowering this biomarker with daily administration of CoQ10 for 3 days prior to elective vascular surgery will reduce adverse outcomes following the operation.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

NT-Pro BNP Predicts Myocardial Injury Post-vascular Surgery and is Reduced with CoQ<sub>10</sub>: A Randomized Double-Blind Trial.
Khan A, Johnson DK, Carlson S, Hocum-Stone L, et al · · 2020 · cited 19× · PMID 31629852 · DOI 10.1016/j.avsg.2019.09.017
Dynamic regulation and targeted interventions of macrophages in ischemia-reperfusion injury.
Lu P, Shen R, Yang J, Wu L, et al · · 2026 · cited 4× · PMID 40348125 · DOI 10.1016/j.jare.2025.05.006
Preoperative C-Reactive Protein Levels Predict Readmission Following Elective Vascular Surgery
mcfalls e, Khan A, Green DL, Santilli S, et al · · 2021 · DOI 10.21203/rs.3.rs-711800/v1

Verify or expand the search:

Other trials of Ubiquinone

Trials testing the same drug.

NCT06640465 — Comparing the Effects of Commercially Available Dietary Supplements on CoQ10 Concentrations · Phase 2, PHASE3 · completed

Other recruiting trials for Myocardial Injury

Currently open trials in the same condition.

NCT06982404 — ZeroHeart Biopsy - Prediction of Deceased Donor Heart Transplant Performance From Organ Donors Using Pre-Transplant Biop · recruiting
NCT06279000 — Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery · Phase 3 · recruiting
NCT06954103 — Mechanisms And Prognosis of Stroke-Heart Syndrome · recruiting
NCT06705023 — Study to Assess Safety and Efficacy of Treating Symptomatic, Ischemic, Chronic Congestive Heart Failure Patients with an · Phase 2 · recruiting
NCT06296212 — Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial In · Phase 3 · recruiting

Other Minneapolis Veterans Affairs Medical Center trials

Trials by the same sponsor.

NCT06568250 — Reaching Rural Veterans: Applying Mind-Body Skills for Pain Using a Whole Health Telehealth Intervention - UG3 Pilot Stu · NA · completed
NCT05290831 — Changes in Heart Rate Variability And Heart Rate/Activity Slope After Hospitalization for Acute Exacerbations of COPD · NA · unknown
NCT04840108 — Veteran Support for Smoking Cessation Pilot Project (VAntage Pilot) · NA · unknown
NCT03960658 — Ketamine and Prolonged Exposure in PTSD · Phase 1, PHASE2 · completed
NCT03673371 — Women's-Specific Footwear With Prosthetic Feet · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03956017 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Minneapolis Veterans Affairs Medical Center
Last refreshed: 31 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03956017.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing